MedTrace Logo

Aspirin Mouthwash in Treating Patients With Oral Leukoplakia

NCT01238185 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Aspirin mouthwash may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of aspirin mouthwash in treating patients with oral leukoplakia.

Conditions

  • Precancerous Condition

Interventions

DRUG

acetylsalicylic acid

GENETIC

gene expression analysis

GENETIC

protein expression analysis

OTHER

laboratory biomarker analysis

OTHER

questionnaire administration

PROCEDURE

biopsy

Sponsors & Collaborators

  • Institute of Head and Neck Studies and Education, United Kingdom

    lead OTHER

Principal Investigators

  • Hisham Mehanna, MD · Institute of Head and Neck Studies and Education, United Kingdom

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01238185 on ClinicalTrials.gov